| Literature DB >> 36188647 |
Viktoria Olexandrivna Yuzko1,2, Olexandr Mykhailovych Yuzko1,2, Tamara Anatoliivna Yuzko2, Svitlana Hryhorivna Pryimak1, Natalia Serhiivna Voloshynovych1, Svitlana Ivanivna Chobaniuk1.
Abstract
A retrospective analysis of medical records of infertile patients using assisted reproductive technologies and melatonin was performed. 76 infertile women were examined. Group 1 included 33 patients who received 3 mg of melatonin two weeks before and during ovulation induction, and group 2 included 43 patients who did not take melatonin. The average age of patients in the groups did not differ. The data of gynecological and ultrasound examinations, structure and thickness of the endometrium, antral follicle count, hormone levels: anti-mullerian, follicle-stimulating, luteinizing, progesterone, estradiol, prolactin, thyrotropin, and thyroxine were evaluated. The primary infertility incidence was significantly higher in all examined patients. Patients in the first group tended to decrease ovarian reserve, recurrent loss, and unexplained infertility; in the second group, more endometriosis, tubal and male infertility factors were observed. The incidence of extragenital pathology in the examined patients did not differ as well as antral follicle count and the thickness of the endometrium. We also did not find any significant difference in the level of hormones in the blood of the examined women, except that patients taking melatonin had significantly higher levels of lutropin but lower levels of the anti-mullerian hormone in the blood. ©2022 JOURNAL of MEDICINE and LIFE.Entities:
Keywords: AMH – anti-mullerian hormone; ART – assisted reproductive technologies; E2 – estradiol; FSH – follicle-stimulating hormone; LH – luteinizing hormone; NAF – number of antral follicles; P – progesterone; PRL – prolactin; T4 – thyroxine; TSH – thyroid-stimulating hormone; assisted reproductive technologies; infertility; melatonin
Mesh:
Substances:
Year: 2022 PMID: 36188647 PMCID: PMC9514810 DOI: 10.25122/jml-2022-0154
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
The incidence of primary and secondary infertility in the women examined.
| Infertility, % | Group 1, n=33 | Group 2, n=43 |
|---|---|---|
|
| 72.72±7.75 | 62.79±7.35 |
|
| 27.27±7.75 | 37.21±7.35 |
Reasons for in vitro fertilization use in infertile patients, %, M±m
| Reasons for infertility | Group 1, n=33 | Group 2, n=43 |
|---|---|---|
|
| 9.09±5.03 | 16.28±5.74 |
|
| 21.21±7.11 | 37.21±7.45 |
|
| 15.15±6.35 | 23.26±6.53 |
|
| 6.06±4.14 | 2.33±2.24 |
|
| 12.12±5.75 | 11.63±4.94 |
|
| 12.12±5.73 | 4.65±3.23 |
|
| 18.18±6.74 | 4.65±3.25 |
|
| 3.03±3.01 | - |
|
| 3.03±3.02 | - |
Extragenital disease in the examined patients, %, M±m.
| Indexes | Group 1, n=33 | Group 2, n=43 |
|---|---|---|
|
| ||
| Autoimmune thyroiditis | 6.06±4.13 | - |
| Hypothyroidism | 3.03±3.03 | - |
| Goiter | 15.15±6.31 | 6.98±3.92 |
| Hyperthyroidism | 3.03±3.01 | - |
|
| ||
| Pyelonephritis | 15.15±6.33 | 4.65±3.24 |
| Cystitis | 3.03±3.02 | - |
|
| 15.15±6.32 | 2.33±2.24 |
|
| 6.06±4.13 | 9.30±4.54 |
|
| 6.06±4.12 | 4.65±3.23 |
|
| 3.03±3.01 | 4.65±3.24 |
|
| 3.03±3.02 | 2.33±2.25 |
Ultrasound examination data (M±m).
| Indexes | Group 1, n=33 | Group 2, n=43 |
|---|---|---|
| The number of antral follicles in the ovary | ||
|
| 6.92±1.05 | 7.74±0.91 |
|
| 7.24±1.06 | 7.93±0.91 |
| Endometrium, mm | 7.13±1.06 | 6.92±0.92 |
The level of hormones in women's blood.
| Indexes | Group 1, n/M±m | Group 2, n/M±m |
|---|---|---|
| FSH, mIU/ml | 25/7.54±0.56 | 43/8.15±0.63 |
| LH, mIU/ml | 25/8.64±0.15 | 40/8.83±0.10 |
| E2, pg/ml | 22/66.21±7.31 | 36/52.71±4.12 |
| PRL, ng/ml | 32/17.94±1.49 | 41/18.83±1.48 |
| P, ng/ml | 23/0.62±0.052 | 37/0.41±0.012 |
| AMH, ng/ml | 32/3.43±0.29 | 42/8.44±0.23* |
| TSH, nmol/l | 10/1.84±0.16 | 12/1/52±0.11 |
| T4, nmol/l | 8/2.52±0.40 | 8/2.53±0.24 |
– significant difference between groups (p<0.001).